<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455104</url>
  </required_header>
  <id_info>
    <org_study_id>CFDI 001 - NR</org_study_id>
    <nct_id>NCT00455104</nct_id>
  </id_info>
  <brief_title>Canadian Fabry Disease Initiative (CFDI) National Registry</brief_title>
  <acronym>CFDI-NR</acronym>
  <official_title>Canadian Fabry Disease Initiative National Registry: Outcomes of Rare Disease Therapeutics and Cardiovascular Risk Factor Modification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Fabry Research Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Fabry Research Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CFDI NATIONAL REGISTRY&#xD;
&#xD;
      Fabry disease is a rare, inherited, genetic condition due to a deficiency of an enzyme called&#xD;
      alpha-galactosidase A. This enzyme deficiency causes the small blood vessels to accumulate a&#xD;
      substance called glycolipid. Without sufficient levels of the enzyme, alpha-galactosidase A,&#xD;
      persons with Fabry Disease develop severe neuropathic pain, kidney disease, heart disease,&#xD;
      stroke and/or premature death; often before the age of 60.&#xD;
&#xD;
      Fabry Disease is estimated to affect approximately one out of every 40,000 males and up to&#xD;
      twice as many females in Canada. We do not have the exact number of persons in Canada who&#xD;
      have this disease. A common problem in studying rare conditions is the difficulty in&#xD;
      identifying the majority of people suffering from such a disease. Gathering their health&#xD;
      information in order to better understand the natural disease progression and its response to&#xD;
      treatment is difficult.&#xD;
&#xD;
      Early ERT studies involving humans had small numbers of subjects and the studies were of&#xD;
      short duration. The results of these clinical studies did lead to approval of the therapy in&#xD;
      many countries around the world including Canada. To date though, evidence of the usefulness&#xD;
      of ERT and its direct impact on the natural course of Fabry disease has been limited, while&#xD;
      its cost continues to be very high. As a result of these issues, there will need to be&#xD;
      continued and long-term collection of information related to the effectiveness of ERT and&#xD;
      other treatments to better document its true clinical outcomes in Canadian people with Fabry&#xD;
      disease.&#xD;
&#xD;
      The Canadian Fabry Disease Initiative National Registry (CFDI-NR) is an observational,&#xD;
      voluntary registry designed to collect outcomes data on Fabry disease from people living in&#xD;
      Canada.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CFDI NATIONAL REGISTRY: Canada-Wide Patient Recruitment&#xD;
&#xD;
      There are over 600 people in Canada known to have Fabry Disease. For more details about Fabry&#xD;
      Disease, please refer to the &quot;Brief Summary.&quot;&#xD;
&#xD;
      The goals of this nation-wide study are as follows:&#xD;
&#xD;
        1. To maintain an established national registry which will collect information related to&#xD;
           the identification and monitoring of all persons with Fabry disease in Canada;&#xD;
&#xD;
        2. To determine clinical outcomes of patients with Fabry disease including those on&#xD;
           treatment;&#xD;
&#xD;
        3. To determine if urine and plasma Gb3 and globotriasylsphingosine (LysoGb3) and their&#xD;
           analogues can be biomarkers for Fabry disease and can predict clinical outcomes.&#xD;
&#xD;
      Data will be collected at baseline and every 12 months, as follows:&#xD;
&#xD;
        -  Medical History&#xD;
&#xD;
        -  Physical examination&#xD;
&#xD;
        -  Neurological exam&#xD;
&#xD;
        -  Electrocardiogram (ECG) - an electrical tracing of one's heart rhythm&#xD;
&#xD;
        -  Echocardiogram (ultrasound of the heart)&#xD;
&#xD;
        -  Holter monitor&#xD;
&#xD;
        -  Magnetic Resonance Imaging (MRI) or CT Scan of the head&#xD;
&#xD;
        -  Lab tests (including alpha-galactosidase levels)&#xD;
&#xD;
        -  Review of current medications&#xD;
&#xD;
        -  24-hour urine collection or a random spot urine test&#xD;
&#xD;
        -  Biomarker samples&#xD;
&#xD;
      To date though, evidence of the usefulness of ERT and its direct impact on the natural course&#xD;
      of Fabry disease has been limited, while its cost continues to be very high (approximately&#xD;
      $300,000 CDN per year per patient). As a result of these issues, there will need to be&#xD;
      continued and long-term collection of information related to the effectiveness of ERT and&#xD;
      other treatments to better document its true clinical outcomes in Canadian people with Fabry&#xD;
      disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2007</start_date>
  <completion_date type="Anticipated">October 2029</completion_date>
  <primary_completion_date type="Anticipated">October 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>(1) To maintain an established national database for the identification and monitoring of all patients with Fabry disease in Canada.</measure>
    <time_frame>2019</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2) To identify the clinical outcomes of patients with Fabry disease including those on various treatments.</measure>
    <time_frame>2019</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3) To determine if urine and Gb3 and lysoGb3 and their analogues can be biomarkers for Fabry disease and can predict clinical outcomes.</measure>
    <time_frame>2019</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>National Registry</arm_group_label>
    <description>To maintain an established national registry which will collect information related to the identification and monitoring of all persons with Fabry disease in Canada.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is an observational, voluntary registry.</description>
    <arm_group_label>National Registry</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biomarker samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with Fabry disease living in Canada.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Age 5 years and older, up to &amp; including age 85 years; and&#xD;
&#xD;
          -  Able to give informed consent; and&#xD;
&#xD;
          -  A clinical diagnosis of Fabry disease; and&#xD;
&#xD;
          -  Compliance with all the clinic visits, interviews and assessments during the study&#xD;
             period; and&#xD;
&#xD;
          -  A Canadian citizen or a landed immigrant&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Inability to give informed consent; or&#xD;
&#xD;
          -  Problem complying with all the clinic visits, interviews and assessments during the&#xD;
             study period; or&#xD;
&#xD;
          -  An estimated life expectancy of less than 12 months&#xD;
&#xD;
          -  Under 5 years of age&#xD;
&#xD;
          -  Non-disease causing mutation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael L West, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Elizabeth II Health Sciences Centre (Capital District Health Authority), Halifax, Nova Scotia, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael L. West, MD</last_name>
    <phone>902-473-4023</phone>
    <email>mlwest@dal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaye Le Moine, RN</last_name>
    <phone>902-473-5770</phone>
    <email>kaye.lemoine@cdha.nshealth.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aneal Khan, MD</last_name>
      <phone>403-955-7211</phone>
      <email>aneal.khan@albertahealthservices.ca</email>
    </contact>
    <contact_backup>
      <last_name>Colleen McNeil</last_name>
      <phone>403-955-7941</phone>
      <email>colleen.mcneil@albertahealthservices.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Aneal Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital Adult Metabolic Diseases Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Sirrs, MD</last_name>
      <phone>604-875-5965</phone>
      <email>sandra.sirrs@vch.ca</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Paquin, RN</last_name>
      <phone>604-875-5965</phone>
      <email>wendy.paquin@vch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sandra Sirrs, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael L West, MD</last_name>
      <phone>902-473-4023</phone>
      <email>mlwest@dal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Laurie Kay, RN</last_name>
      <phone>902-473-2082</phone>
      <email>laurie.kay@cdha.nshealth.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Michael L West, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark R. Iwanochko, MD, FRCPC</last_name>
      <phone>416-603-5236</phone>
      <email>robertmark.iwanochko@uhn.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Syed Wasim</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>4231</phone_ext>
      <email>syed.wasim@sickkids.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Mark R Iwanochko, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Montreal, Department of Medicine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Bichet, MD</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>2173</phone_ext>
      <email>daniel.bichet@umontreal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Carole Fortier, RN</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>3110</phone_ext>
      <email>c-fortier@crhsc.rtss.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Bichet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.garrod.ca</url>
    <description>Fabry Disease: recommendations for diagnosis, management, and enzyme replacement therapy in Canada Nov 2005</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 30, 2007</study_first_submitted>
  <study_first_submitted_qc>March 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2007</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry Disease</keyword>
  <keyword>National Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

